Cargando…
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with methods enabling correct heavy-chain association usi...
Autores principales: | Surowka, Marlena, Schaefer, Wolfgang, Klein, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425689/ https://www.ncbi.nlm.nih.gov/pubmed/34491877 http://dx.doi.org/10.1080/19420862.2021.1967714 |
Ejemplares similares
-
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
por: Klein, Christian, et al.
Publicado: (2016) -
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
por: Sustmann, Claudio, et al.
Publicado: (2019) -
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
por: Regula, Jörg T, et al.
Publicado: (2016) -
Detailed Analytical Characterization of a Bispecific
IgG1 CrossMab Antibody of the Knob-into-Hole Format Applying Various
Stress Conditions Revealed Pronounced Stability
por: Grunert, Ingrid, et al.
Publicado: (2022) -
Variable heavy–variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly
por: Regula, Joerg Thomas, et al.
Publicado: (2018)